Structures by: Braun D. E.
Total: 61
Codeine Monohydrate
C18H21NO3,H2O
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=10.3994(2)Å b=12.5671(2)Å c=12.0640(2)Å
α=90° β=90° γ=90°
Codeine Hydrochloride Dihydrate
C18H22NO31,Cl1,2(H2O)
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=6.7621(5)Å b=12.9315(9)Å c=20.3080(14)Å
α=90° β=90° γ=90°
Codeine Hydrochloride Anhydrate I
C18H22NO3,Cl
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=7.14435(17)Å b=13.2304(3)Å c=16.5408(4)Å
α=90° β=90° γ=90°
Ethylmorphine Monohydrate
C19H23NO3,H2O
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=7.08246(18)Å b=13.1493(3)Å c=18.0581(5)Å
α=90° β=90° γ=90°
Ethylmorphine Hydrochloride Dihydrate
C19H24NO3,Cl,2(H2O)
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=6.8715(2)Å b=13.3924(4)Å c=20.4176(5)Å
α=90° β=90° γ=90°
1,3,5-trihydroxybenzene dihydrate
C6H6O3,2(H2O)
The journal of physical chemistry. B (2012) 116, 13 3961-3972
a=6.6209(17)Å b=13.5606(25)Å c=8.0462(15)Å
α=90° β=90° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Hydrate A 1.95
C22H25N3O3,H3.90O1.95
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=26.663(7)Å b=9.634(2)Å c=20.863(9)Å
α=90° β=128.322(6)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Dihydrate
C22H25N3O3,2(H2O)
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=13.212(2)Å b=9.1505(15)Å c=18.160(3)Å
α=90° β=105.195(11)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid Hydrate A 1.73
C22H25N3O3,H3.46O1.73
Molecular pharmaceutics (2015) 12, 8 3069-3088
a=26.498(3)Å b=9.6469(8)Å c=20.342(3)Å
α=90° β=128.706(4)° γ=90°
C7H11N2OS,Br
C7H11N2OS,Br
CrystEngComm (2020)
a=11.2359(2)Å b=14.9020(2)Å c=12.3361(3)Å
α=90° β=111.2210(10)° γ=90°
C7H11N2OS,Cl
C7H11N2OS,Cl
CrystEngComm (2020)
a=11.1116(2)Å b=14.6502(3)Å c=12.1138(4)Å
α=90° β=111.270(2)° γ=90°
C5H9N4OS,Br
C5H9N4OS,Br
CrystEngComm (2020)
a=5.8057(3)Å b=19.4234(11)Å c=8.3009(5)Å
α=90° β=102.153(5)° γ=90°
C7H11N2OS,Cl
C7H11N2OS,Cl
CrystEngComm (2020)
a=17.1960(8)Å b=8.4197(5)Å c=6.6408(3)Å
α=90° β=95.281(4)° γ=90°
Aprepitant, form II
C23H21F7N4O3
New Journal of Chemistry (2008) 32, 10 1677
a=7.7768(16)Å b=7.4072(11)Å c=21.297(5)Å
α=90° β=92.861(17)° γ=90°
Aprepitant, form I
C23H21F7N4O3
New Journal of Chemistry (2008) 32, 10 1677
a=7.421(4)Å b=7.710(4)Å c=42.200(2)Å
α=90° β=90° γ=90°
3-(3-methylimidazolium-1-yl)propanoate dihydrate
C7H10N2O2,2(H2O)
CrystEngComm (2018) 20, 48 7826
a=7.3825(4)Å b=8.4170(4)Å c=8.8371(4)Å
α=113.2550(10)° β=105.1800(10)° γ=95.990(2)°
3-(3-methylimidazolium-1-yl)propanoate
C7H10N2O2
CrystEngComm (2018) 20, 48 7826
a=6.6643(4)Å b=8.7065(5)Å c=12.8000(8)Å
α=90° β=90° γ=90°
3-(3-methylimidazolium-1-yl)propanoate monohydrate
C7H10N2O2,H2O
CrystEngComm (2018) 20, 48 7826
a=7.7258(7)Å b=12.6758(12)Å c=8.8421(9)Å
α=90° β=105.550(10)° γ=90°
1 (2 carboxyethyl)-3-methylimidazolium chloride
C7H11N2O2,Cl
CrystEngComm (2018) 20, 48 7826
a=20.1911(9)Å b=7.9146(3)Å c=22.5627(11)Å
α=90° β=92.268(2)° γ=90°
Dapsone nitromethane hemisolvate
2(C12H12N2O2S),CH3NO2
CrystEngComm (2019) 21, 36 5533
a=8.4167(2)Å b=16.3415(3)Å c=19.1383(4)Å
α=90° β=95.832(2)° γ=90°
Dapsone acetonitrile hemisolvate
2(C12H12N2O2S),C2H3N
CrystEngComm (2019) 21, 36 5533
a=8.5132(2)Å b=16.1830(3)Å c=18.9865(4)Å
α=90° β=97.818(2)° γ=90°
Cinacalcet HCl acetic acid solvate
C24H27ClF3NO2
CrystEngComm (2008) 10, 11 1617
a=7.5434(8)Å b=18.575(2)Å c=16.7756(19)Å
α=90° β=90° γ=90°
Isonicotinamide
C6H6N2O
CrystEngComm (2011) 13, 23 6923
a=11.0819(6)Å b=7.9976(4)Å c=9.9850(5)Å
α=90° β=94.0480(10)° γ=90°
C6H6N2O1
C6H6N2O1
CrystEngComm (2011) 13, 23 6923
a=5.1923(11)Å b=9.466(3)Å c=12.259(3)Å
α=90.00° β=91.217(7)° γ=90.00°
(Antipyrine)(4-Aminobenzoic acid)
C11H12N2O,C7H7NO2
CrystEngComm (2012) 14, 7 2454
a=9.5767(12)Å b=12.7646(17)Å c=13.9388(18)Å
α=90.00° β=90.758(2)° γ=90.00°
(2,2'-Bipyridine)(Succinic acid)
C10H8N2,C4H6O4
CrystEngComm (2012) 14, 7 2454
a=8.958(3)Å b=5.1788(14)Å c=14.357(4)Å
α=90.00° β=106.109(4)° γ=90.00°
2(Phenazine)(4-Aminobenzoic acid)
2(C12H8N2),C7H7NO2
CrystEngComm (2012) 14, 7 2454
a=15.557(2)Å b=17.056(3)Å c=19.782(3)Å
α=80.658(5)° β=78.559(7)° γ=77.168(6)°
2(Diphenylcyclopropenone)(Succinic Acid)
C15H10O,0.5(C4H6O4)
CrystEngComm (2012) 14, 7 2454
a=14.654(4)Å b=5.5540(14)Å c=16.288(4)Å
α=90.00° β=90.471(4)° γ=90.00°
4-aminoquinaldine monohydrate
C10H10N2,H2O
CrystEngComm (2016) 18, 22 4053
a=4.7832(5)Å b=12.0775(4)Å c=16.3371(5)Å
α=90.00000° β=92.226(3)° γ=90.00000°
Cytosine/5-flucytosine solid solution I
C4H4.359F0.641N3O1
CrystEngComm (2017)
a=4.00808(9)Å b=9.43931(11)Å c=13.0306(2)Å
α=90° β=91.179(2)° γ=90°
Cytosine/5-flucytosine solid solution I
C4H4.393F0.607N3O1
CrystEngComm (2017)
a=6.67372(5)Å b=6.67372(5)Å c=23.6290(3)Å
α=90° β=90° γ=90°
C12H10F13N2S,I
C12H10F13N2S,I
Green Chem. (2017)
a=6.4269(3)Å b=8.9443(5)Å c=16.3677(9)Å
α=85.570(5)° β=81.795(4)° γ=86.766(5)°
C12H10F13N2S1,Cl1
C12H10F13N2S1,Cl1
Green Chem. (2017)
a=6.3654(4)Å b=9.2363(5)Å c=16.0361(12)Å
α=75.231(5)° β=83.709(5)° γ=76.855(5)°
2(C12H10F13N2S1),SiF62
2(C12H10F13N2S1),SiF62
Green Chem. (2017)
a=18.463(5)Å b=8.901(3)Å c=11.595(3)Å
α=90° β=102.185(9)° γ=90°
C20H13F26IN2S
C20H13F26IN2S
Green Chem. (2017)
a=5.8881(3)Å b=10.2741(7)Å c=25.4810(10)Å
α=89.763(4)° β=87.419(4)° γ=77.726(3)°
C12H10F13N2S1,C8F17I,I1
C12H10F13N2S1,C8F17I,I1
Green Chem. (2017)
a=6.4954(5)Å b=9.2039(8)Å c=27.9195(19)Å
α=94.848(6)° β=91.767(6)° γ=95.367(7)°
C15H15F13N2O3S2
C15H15F13N2O3S2
Green Chem. (2017)
a=8.6657(2)Å b=10.1187(4)Å c=48.601(2)Å
α=90° β=90° γ=90°
4-aminoquinaldine form I
C10H10N2
CrystEngComm / RSC (2015) 17, 12 2504-2516
a=5.2162(4)Å b=12.3693(9)Å c=13.1192(9)Å
α=90° β=99.065(3)° γ=90°
4-aminoquinaldine form II
C10H10N2,C0.08Cl0.33
CrystEngComm / RSC (2015) 17, 12 2504-2516
a=28.4074(8)Å b=28.4074(8)Å c=11.9126(5)Å
α=90° β=90° γ=120°
Morphine
C17H19NO3
Acta Crystallographica Section E (2013) 69, 1 o2
a=7.6989(10)Å b=12.737(4)Å c=13.740(4)Å
α=90.00° β=90.00° γ=90.00°
Morphine hydrochloride anhydrate
C17H20NO3,Cl
Acta Crystallographica Section E (2012) 68, 12 o3358-o3359
a=7.3504(2)Å b=12.8524(5)Å c=16.0372(5)Å
α=90.00° β=90.00° γ=90.00°
3-(4-(benzo[d]isoxazole-3-yl)piperazin-1-yl)-2,2-dimethylpropanoic acid
C16H21N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=14.0905(3)Å b=6.25060(10)Å c=17.0170(3)Å
α=90° β=91.3210(10)° γ=90°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid
C22H25N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=9.3970(3)Å b=10.8925(3)Å c=11.0095(4)Å
α=65.728(2)° β=67.321(2)° γ=77.584(2)°
3-(4-dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpropanoic acid
C22H25N3O3
Crystal Growth & Design (2014) 14, 4 2056
a=9.2754(4)Å b=10.0504(5)Å c=11.8580(6)Å
α=106.010(4)° β=108.236(3)° γ=99.895(3)°
Creatine anhydrate B
C4H9N3O2
Crystal Growth & Design (2014) 14, 10 4895
a=5.4857(3)Å b=11.4417(4)Å c=9.9624(5)Å
α=90.00000° β=98.663(5)° γ=90.00000°
Creatine anhydrate form C
C4H9N3O2
Crystal Growth & Design (2014) 14, 10 4895
a=11.9504(3)Å b=5.3453(2)Å c=9.5314(3)Å
α=90.00000° β=90.00000° γ=90.00000°
Naproxen
C14H14O3
Crystal Growth & Design (2011) 11, 12 5659
a=25.8301(13)Å b=15.4939(4)Å c=5.9465(2)Å
α=90° β=90° γ=90°
Beta resoryclic acid form I
C7H6O4
Crystal growth & design (2011) 11, 1 210-220
a=23.1978(4)Å b=5.5469(1)Å c=5.1980(1)Å
α=90° β=92.215(1)° γ=90°
Beta resoryclic acid hemihydrate
2(C7H6O4),H2O
Crystal growth & design (2011) 11, 1 210-220
a=7.0270(4)Å b=9.5449(4)Å c=11.1763(5)Å
α=96.684(4)° β=104.319(5)° γ=98.903(4)°
Beta resoryclic DMSO hemisolvate
2(C7H6O4),C2H6OS
Crystal growth & design (2011) 11, 1 210-220
a=6.39832(12)Å b=11.7099(3)Å c=23.2362(5)Å
α=90° β=90° γ=90°
Beta resoryclate pyridinium salt
C7H5O4,C5H6N
Crystal growth & design (2011) 11, 1 210-220
a=11.7363(4)Å b=8.5691(2)Å c=11.8310(4)Å
α=90° β=115.973(5)° γ=90°
3,4,5-trihydroxybenzoic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=25.685(3)Å b=4.9273(5)Å c=11.2508(12)Å
α=90° β=106.234(2)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=5.2303(1)Å b=5.26495(12)Å c=24.7927(4)Å
α=90° β=102.1116(17)° γ=90°
Gallic acid
C7H6O5,H2O
Crystal growth & design (2013) 13, 1 19-23
a=7.60719(9)Å b=3.64133(4)Å c=26.7915(4)Å
α=90° β=98.4212(11)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=7.31853(19)Å b=8.2536(2)Å c=11.7148(3)Å
α=100.4719(12)° β=90.2335(17)° γ=90.9844(17)°
Methyl paraben
C8H8O3
Crystal growth & design (2013) 13, 3 1206-1217
a=4.8980(8)Å b=14.698(2)Å c=10.3341(16)Å
α=90.00° β=98.774(4)° γ=90.00°
Methyl paraben
C8H8O3
Crystal growth & design (2013) 13, 3 1206-1217
a=17.517(5)Å b=7.2602(18)Å c=6.224(2)Å
α=90.00° β=107.61(3)° γ=90.00°
Methyl paraben
C8H8O3
Crystal growth & design (2013) 13, 3 1206-1217
a=5.9845(6)Å b=8.3384(6)Å c=14.4209(12)Å
α=90.00° β=96.526(9)° γ=90.00°
1,3,5-trihydroxybenzene
C6H6O3
Crystal growth & design (2013) 13, 9 4071-4083
a=12.1207(6)Å b=3.80651(13)Å c=13.1647(6)Å
α=90° β=115.478(6)° γ=90°
Pyrogallol_tetartohydrate
4(C6H6O3),H2O
Crystal growth & design (2013) 13, 9 4071-4083
a=24.6058(6)Å b=24.6058(6)Å c=3.8524(3)Å
α=90° β=90° γ=90°